AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33094666 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 33094666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32692124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) intervention involving weekly individual sessions with a therapist and practice of computerized CR exercises between sessions.
Number of subjects: 20
Study 32692124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) intervention
Number of subjects: 20
Study 33742060 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular hydrogen (H2) supplement
Number of subjects: 10
Study 36316077 — intervention group
Group type: EXPERIMENTAL
Intervention: Online individualised therapy group (ITG) receiving professional advice on LBP and musculoskeletal problems via online interview and email for 6 months.
Number of subjects: 120
Study 36316077 — intervention group
Group type: COMPARATOR
Intervention: Usual group (UG) with access to brochures and video feeds related to LBP and fall prevention.
Number of subjects: 120
Study 32746799 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE) including text messaging and print materials
Number of subjects: 720
Study 32746799 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE) plus primary care physician activation (PAE + Phys)
Number of subjects: 720
Study 32746799 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE) plus primary care physician activation (PAE + Phys) plus teledermoscopy (PAE + Phys + TD)
Number of subjects: 720
Study 35278462 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the right cerebellum
Number of subjects: 36
Study 35278462 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 36
Study 35278462 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 36
Study 32469166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) treatment
Number of subjects: 30
Study 32469166 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 subjects)
Number of subjects: 30
Study 33781238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (CE: quadriceps strengthening exercises (QSE) and Baduanjin qigong training (BDJ))
Number of subjects: 128
Study 33781238 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening exercises (QSE)
Number of subjects: 128
Study 33781238 — intervention group
Group type: COMPARATOR
Intervention: Baduanjin qigong training (BDJ)
Number of subjects: 128
Study 34225091 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise trial after adjuvant treatment
Number of subjects: 342
Study 34225091 — intervention group
Group type: COMPARATOR
Intervention: Age-matched general female population (n = 892)
Number of subjects: 342
Study 34125440 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate endoscopic dacryocystorhinostomy (En-DCR)
Number of subjects: 160
Study 34125440 — intervention group
Group type: COMPARATOR
Intervention: Delayed endoscopic dacryocystorhinostomy (En-DCR) after 2 to 5 days of antibiotic treatment
Number of subjects: 160
Study 33904998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh tail crossing (group C)
Number of subjects: 116
Study 33904998 — intervention group
Group type: COMPARATOR
Intervention: No mesh tail crossing (group N)
Number of subjects: 116
Study 36096863 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 44
Study 36096863 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 44
Study 32009442 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual computer magnanimous therapy
Number of subjects: 0
Study 32009442 — intervention group
Group type: EXPERIMENTAL
Intervention: Group computer magnanimous therapy
Number of subjects: 0
Study 32327474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist assessment every 8 weeks for 12 months
Number of subjects: 39
Study 32327474 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39
Study 32327474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist assessment
Number of subjects: 39
Study 34902530 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks)
Number of subjects: 501
Study 34902530 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 501
Study 34902530 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 501
Study 34902530 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study 34845428 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMDC (Autologous Bone Marrow-Derived Chondrocytes), single injection of 5 million
Number of subjects: 60
Study 34845428 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment they were taking)
Number of subjects: 60
Study 33190160 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal at night (N=12; 7 males)
Number of subjects: 39
Study 33190160 — intervention group
Group type: COMPARATOR
Intervention: Snack at night (N=13; 7 males)
Number of subjects: 39
Study 33190160 — intervention group
Group type: COMPARATOR
Intervention: No eating at night (N=14; 9 males)
Number of subjects: 39
Study 32271318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedated reduction
Number of subjects: 319
Study 32271318 — intervention group
Group type: COMPARATOR
Intervention: Nonsedated immobilization
Number of subjects: 319
Study 33184667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led weight loss intervention (n = 11)
Number of subjects: 22
Study 33184667 — intervention group
Group type: COMPARATOR
Intervention: Usual WIC care (n = 11)
Number of subjects: 22
Study 32308128 — intervention group
Group type: EXPERIMENTAL
Intervention: SEC‐coated circuit (SEC group)
Number of subjects: 20
Study 32308128 — intervention group
Group type: COMPARATOR
Intervention: Heparin‐coated circuit (control group)
Number of subjects: 20
Study 36253971 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 40 mL of 0.375% ropivacaine
Number of subjects: 60
Study 36253971 — intervention group
Group type: COMPARATOR
Intervention: Control group with 40 mL of normal saline
Number of subjects: 60
Study 36253971 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 60
Study 36253971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34371382 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert Breast Cancer STRAT4 (RT-qPCR detection of mRNA)
Number of subjects: 1115
Study 34371382 — intervention group
Group type: COMPARATOR
Intervention: Central IHC (and ISH for HER2 IHC 2+)
Number of subjects: 1115
Study 32905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac (750 mg eflornithine, 150 mg sulindac, both once daily for up to 48 months)
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Sulindac (150 mg once daily for up to 48 months)
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine (750 mg once daily for up to 48 months)
Number of subjects: 171
Study 32905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac vs Sulindac
Number of subjects: 171
Study 32905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac vs Eflornithine
Number of subjects: 171
Study 32905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac in precolectomy patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Sulindac in precolectomy patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine in precolectomy patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac in rectal or ileal pouch polyposis patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Sulindac in rectal or ileal pouch polyposis patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine in rectal or ileal pouch polyposis patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac in duodenal polyposis patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Sulindac in duodenal polyposis patients
Number of subjects: 171
Study 32905675 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine in duodenal polyposis patients
Number of subjects: 171
Study 35980649 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin (EP) - etoposide (100 mg/m2/d on days 1, 2, and 3) and cisplatin (80 mg/m2/d on day 1) every 3 weeks
Number of subjects: 170
Study 35980649 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (IP) - irinotecan (60 mg/m2/d on days 1, 8, and 15) and cisplatin (60 mg/m2/d on day 1) every 4 weeks
Number of subjects: 170
Study 35980649 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 170
Study 35980649 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 170
Study 33600205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (offline) to the prefrontal cortex
Number of subjects: 0
Study 33600205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (offline) to the superior medial frontal cortex (SMFC)
Number of subjects: 0
Study 33600205 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation targeting the SMFC
Number of subjects: 0
Study 32349711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the dorsal branch of the cephalic vein
Number of subjects: 115
Study 32349711 — intervention group
Group type: COMPARATOR
Intervention: No ligation of the dorsal branch of the cephalic vein
Number of subjects: 115
Study 36088297 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) + intercostal nerve block (ICNB)
Number of subjects: 173
Study 36088297 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) + intercostal nerve block (ICNB)
Number of subjects: 173
Study 36088297 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve block (ICNB)
Number of subjects: 173
Study 33164569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 448
Study 33164569 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 448
Study 33944585 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (5 sessions over 3 weeks)
Number of subjects: 17
Study 33944585 — intervention group
Group type: COMPARATOR
Intervention: Bulk training (2 sessions within 3 days)
Number of subjects: 17
Study 34582715 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily)
Number of subjects: 367
Study 34582715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 34582715 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix with add-back therapy
Number of subjects: 367
Study 32365403 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally processed vegetables
Number of subjects: 100
Study 34750975 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook‐based intervention (FIIT)
Number of subjects: 60
Study 34750975 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 60
Study 33051814 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration anesthesia (1.5 ml of 2% lidocaine with 1:80,000 epinephrine)
Number of subjects: 66
Study 33051814 — intervention group
Group type: COMPARATOR
Intervention: Buccal and lingual infiltration anesthesia (1.5 ml of 2% lidocaine with 1:80,000 epinephrine by buccal injection and 0.3 ml of the same solution injected into the lingual side)
Number of subjects: 66
Study 36346210 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose isotretinoin (0.6 mg/kg/day)
Number of subjects: 100
Study 36346210 — intervention group
Group type: COMPARATOR
Intervention: Low dose isotretinoin (0.3 mg/kg/day)
Number of subjects: 100
Study 33413515 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin sponge impregnated with mixed anti-inflammatory drugs
Number of subjects: 128
Study 33413515 — intervention group
Group type: COMPARATOR
Intervention: Saline immersed in gelatin sponge (control)
Number of subjects: 128
Study 32844217 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive forearm loading
Number of subjects: 21
Study 32844217 — intervention group
Group type: COMPARATOR
Intervention: Nonloading controls
Number of subjects: 21
Study 35473369 — intervention group
Group type: EXPERIMENTAL
Intervention: VPEP-E (Violence Prevention Education Program using Empathy), 8 sessions
Number of subjects: 101
Study 35473369 — intervention group
Group type: COMPARATOR
Intervention: Control group (classroom lectures on violence prevention)
Number of subjects: 101
Study 32198968 — intervention group
Group type: COMPARATOR
Intervention: Response Adaptive Randomization (RAR)
Number of subjects: 0
Study 33228560 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV seropositivity
Number of subjects: 732
Study 33228560 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 11-14 years
Number of subjects: 732
Study 33228560 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 22-24 years
Number of subjects: 732
Study 33228560 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-white ethnicity
Number of subjects: 732
Study 33228560 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV seropositivity
Number of subjects: 732
Study 33228560 — intervention group
Group type: COMPARATOR
Intervention: Smoking status, occupation, body mass index, and region of England
Number of subjects: 732
Study 35953474 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclepertin (2, 5, 10, or 25 mg)
Number of subjects: 79
Study 35953474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 32725758 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) treatment
Number of subjects: 22
Study 32725758 — intervention group
Group type: COMPARATOR
Intervention: Usual CAMHS care
Number of subjects: 22
Study 33034639 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple daily sweepstakes group
Number of subjects: 805
Study 33034639 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadline sweepstakes group
Number of subjects: 805
Study 33034639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweepstakes plus deposit contract group
Number of subjects: 805
Study 33034639 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 805
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT weekly
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT twice weekly
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT weekly
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT twice weekly
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT skills
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance
Number of subjects: 200
Study 35228163 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline working memory
Number of subjects: 200
Study 32996689 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dichoptic video game treatment (n = 12)
Number of subjects: 23
Study 32996689 — intervention group
Group type: COMPARATOR
Intervention: Placebo non-dichoptic game (n = 11)
Number of subjects: 23
Study 36178734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM) capsules, 4 mg
Number of subjects: 56
Study 36178734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM) capsules with high-fat meals
Number of subjects: 56
Study 36178734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM) capsules
Number of subjects: 56
Study 33783392 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing voucher receipt
Number of subjects: 0
Study 32597030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy availability (LEA) at 20 kcal/kg fat-free mass (FFM)/day
Number of subjects: 6
Study 32597030 — intervention group
Group type: COMPARATOR
Intervention: Neutral energy availability (NEA) at 45 kcal/kg FFM/day
Number of subjects: 6
Study 32597030 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy availability (LEA)
Number of subjects: 6
Study 36235628 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-rich calcium powder (HCP) (1500 mg, containing 2.544 μg of H2)
Number of subjects: 10
Study 36235628 — intervention group
Group type: COMPARATOR
Intervention: H2-depleted placebo (1500 mg)
Number of subjects: 10
Study 34014694 — intervention group
Group type: EXPERIMENTAL
Intervention: Valued Living (ACT-based group)
Number of subjects: 135
Study 34014694 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 135
Study 32543682 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 203
Study 32543682 — intervention group
Group type: COMPARATOR
Intervention: Standard Blood Glucose Monitoring (BGM)
Number of subjects: 203
Study 34726694 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-HO-RUTF
Number of subjects: 2565
Study 34726694 — intervention group
Group type: COMPARATOR
Intervention: S-RUTF
Number of subjects: 2565
Study 33905487 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted sequencing approach to monitor transposon polymorphisms
Number of subjects: 16
Study 33905487 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture-based assay
Number of subjects: 16
Study 33905487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transposon polymorphisms data integration with gene expression data
Number of subjects: 16
Study 33905487 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed analysis of 18 polymorphisms in a larger association panel
Number of subjects: 16
Study 33905487 — intervention group
Group type: EXPERIMENTAL
Intervention: Luciferase-based expression assay
Number of subjects: 16
Study 36375185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.5 mg (Group M)
Number of subjects: 90
Study 36375185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dexmedetomidine 0.5 µg/kg (Group D)
Number of subjects: 90
Study 36375185 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.5 mg with dexmedetomidine 0.5 µg/kg (Group MD)
Number of subjects: 90
Study 32738955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge-TFF3 procedure
Number of subjects: 13514
Study 32738955 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 13514
Study 33217109 — intervention group
Group type: EXPERIMENTAL
Intervention: Metalinguistic training (N=22)
Number of subjects: 41
Study 33217109 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (N=19)
Number of subjects: 41
Study 33217109 — intervention group
Group type: COMPARATOR
Intervention: Chronological age controls
Number of subjects: 41
Study 35884739 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (ALIC/NAcc-DBS)
Number of subjects: 64
Study 35884739 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 64
Study 32816023 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Number of subjects: 9745
Study 32816023 — intervention group
Group type: COMPARATOR
Intervention: Nonrobotic surgery
Number of subjects: 9745
Study 36397441 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy + Bifidobacterium animalis subsp. lactis CP-9 (n=43; 5×10^9 CFU/capsule)
Number of subjects: 83
Study 36397441 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy + placebo (n=40)
Number of subjects: 83
Study 33542168 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Computer Aided Implantology (SCAI)
Number of subjects: 15
Study 33542168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Computer Aided Implantology (DCAI)
Number of subjects: 15
Study 33542168 — intervention group
Group type: COMPARATOR
Intervention: Free Hand
Number of subjects: 15
Study 33542168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CBCT)
Number of subjects: 15
Study 33542168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral Scan (IOS)
Number of subjects: 15
Study 32762630 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinopyrum bessarabicum-specific EST-STS markers
Number of subjects: 3
Study 32762630 — intervention group
Group type: EXPERIMENTAL
Intervention: Secale anatolicum-specific EST-STS markers
Number of subjects: 3
Study 32762630 — intervention group
Group type: EXPERIMENTAL
Intervention: S. anatolicum-specific markers
Number of subjects: 3
Study 34741731 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 (50-900 mg)
Number of subjects: 8
Study 34741731 — intervention group
Group type: EXPERIMENTAL
Intervention: Active metabolite AS(N-1)3'VIR-2218
Number of subjects: 8
Study 34741731 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218
Number of subjects: 8
Study 34741731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 32958573 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown nuts during Halloween
Number of subjects: 1390
Study 32958573 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown nuts during Easter
Number of subjects: 1390
Study 32958573 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanuts during Halloween
Number of subjects: 1390
Study 32958573 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanuts during Easter
Number of subjects: 1390